The utility of isotope-coded protein labeling for
prioritization of proteins found in ovarian cancer patient urine
Adam Rainczuk
Mark Condina
Matthias Pelzing
Sebastiaan Dolman
Jyothsna Rao
Nicole Fairweather
Tom Jobling
Andrew N. Stephens
10.1021/pr400618v.s001
https://acs.figshare.com/articles/dataset/The_utility_of_isotope_coded_protein_labeling_for_prioritization_of_proteins_found_in_ovarian_cancer_patient_urine/2380774
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization.
2013-09-06 00:00:00
urine proteins
biomarker discovery
immunohistochemical analysis
cancer patient urine
Western blot
cancer patients
biomarker candidates
biomarker discovery studies
tissue microarray
noninvasive sampling
579 proteins
MS
exclusion criteria
ICPL strategy
cancer patient urineUrine
quantitation data
marker candidates
Protein abundance changes
sample type